DOW JONES23,433.57+779.71 3.44%
S&P 5002,749.98+90.57 3.41%
NASDAQ8,090.90+203.64 2.58%

Alpine Immune Sciences' ALPN-101 Receives FDA Orphan Drug Designations For Prevention And Treatment Of Acute Graft Versus Host Disease

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the United States

Benzinga · 03/18/2020 11:17

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the United States Food and Drug Administration (FDA) has made two orphan drug designations for ALPN-101, Alpine's first-in-class selective dual T cell costimulation inhibitor, for the prevention and for the treatment of acute GVHD.